Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
40.72
-0.72 (-1.74%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Qiagen Employees
Qiagen had 5,967 employees as of December 31, 2023. The number of employees decreased by 211 or -3.42% compared to the previous year.
Employees
5,967
Change (1Y)
-211
Growth (1Y)
-3.42%
Revenue / Employee
$331,526
Profits / Employee
$14,009
Market Cap
8.80B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5,967 | -211 | -3.42% |
Dec 31, 2022 | 6,178 | 150 | 2.49% |
Dec 31, 2021 | 6,028 | 418 | 7.45% |
Dec 31, 2020 | 5,610 | 514 | 10.09% |
Dec 31, 2019 | 5,096 | 144 | 2.91% |
Dec 31, 2018 | 4,952 | 264 | 5.63% |
Dec 31, 2017 | 4,688 | 4 | 0.09% |
Dec 31, 2016 | 4,684 | 125 | 2.74% |
Dec 31, 2015 | 4,559 | 220 | 5.07% |
Dec 31, 2014 | 4,339 | 324 | 8.07% |
Dec 31, 2013 | 4,015 | 16 | 0.40% |
Dec 31, 2012 | 3,999 | 61 | 1.55% |
Dec 31, 2011 | 3,938 | 351 | 9.79% |
Dec 31, 2010 | 3,587 | 92 | 2.63% |
Dec 31, 2009 | 3,495 | 454 | 14.93% |
Dec 31, 2008 | 3,041 | 379 | 14.24% |
Dec 31, 2007 | 2,662 | 708 | 36.23% |
Dec 31, 2006 | 1,954 | 365 | 22.97% |
Dec 31, 2005 | 1,589 | 267 | 20.20% |
Dec 31, 2004 | 1,322 | -231 | -14.87% |
Dec 31, 2003 | 1,553 | -98 | -5.94% |
Dec 31, 2002 | 1,651 | 94 | 6.04% |
Dec 31, 2001 | 1,557 | 242 | 18.40% |
Dec 31, 2000 | 1,315 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
QGEN News
- 4 days ago - QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation - Business Wire
- 11 days ago - QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast - Business Wire
- 12 days ago - QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook - Business Wire
- 18 days ago - QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts - Business Wire
- 19 days ago - QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results - Business Wire
- 6 weeks ago - QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio - Business Wire
- 6 weeks ago - QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing - Business Wire
- 7 weeks ago - Qiagen N.V.: Some Clarity Needed Before Buying The Dip - Seeking Alpha